Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 2429Neoplasms 1840Carcinoma, Non-Small-Cell Lung 1615Prostatic Neoplasms 1309Colorectal Neoplasms 1147Lung Neoplasms 991Neoplasm Metastasis 836Multiple Myeloma 801Leukemia, Myeloid, Acute 777Ovarian Neoplasms 682Pancreatic Neoplasms 667Melanoma 667Squamous Cell Carcinoma of Head and Neck 592Recurrence 568Carcinoma, Hepatocellular 568Brain Neoplasms 529Glioblastoma 519Stomach Neoplasms 504Head and Neck Neoplasms 503Triple Negative Breast Neoplasms 472Lymphoma 462Uterine Cervical Neoplasms 454Carcinoma, Renal Cell 429Precursor Cell Lymphoblastic Leukemia-Lymphoma 419Lymphoma, Non-Hodgkin 392Endometrial Neoplasms 385Sarcoma 370Lymphoma, Follicular 358Urinary Bladder Neoplasms 356Lymphoma, Large B-Cell, Diffuse 355

Interventions

abemaciclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Fibrocystic Breast Disease × 1 year × Clear all
NCT03979508 2025-11-12

Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer

Mayo Clinic

Phase 2 Terminated
26 enrolled
Breast

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating, Fibrocystic Breast Disease, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡